Replimune CAO granted options and RSUs
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards.
Rhea-AI Filing Summary
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 91,667 shares
Grant/Award
2 txns
Insider
Schwendenman Andrew
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 55,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 36,667 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 55,000 contracts (Direct);
Common Stock — 114,951 shares (Direct)
Footnotes (2)
- F1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
- F2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Key Figures
Stock options granted: 55,000 options
Option exercise price: $7.61 per share
RSU-related shares granted: 36,667 shares
+2 more
5 metrics
Stock options granted
55,000 options
Employee stock option grant on April 1, 2026
Option exercise price
$7.61 per share
Exercise price for 55,000-share option grant
RSU-related shares granted
36,667 shares
Common stock issuable upon RSU settlement
Shares owned after grants
114,951 shares
Total direct common stock holdings after April 1, 2026
Option expiration date
April 1, 2036
Expiry of employee stock option grant
Key Terms
restricted stock units ("RSUs"), Employee Stock Option (right to buy), vesting, contingent right
4 terms
restricted stock units ("RSUs") financial
"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
vesting financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Replimune (REPL) disclose for Andrew Schwendenman?
Replimune disclosed that Chief Accounting Officer Andrew Schwendenman received equity compensation grants. He was awarded 55,000 stock options and 36,667 restricted stock units, both structured to vest over several years, aligning his incentives with long-term company performance and continued service.
How many stock options did the Replimune (REPL) CAO receive and at what price?
Andrew Schwendenman received an employee stock option covering 55,000 shares of Replimune common stock at an exercise price of $7.61 per share. This option grant vests over time and expires on April 1, 2036, providing potential future share ownership if exercised.
What are the vesting terms of the RSUs granted to the Replimune (REPL) CAO?
The CAO’s RSU grant covers 36,667 shares of common stock. 25% vest on May 15, 2027, with the remaining RSUs vesting in three approximately equal annual installments through May 15, 2030, subject to his continuous service with Replimune.
How do the Replimune (REPL) stock options granted to the CAO vest over time?
For the 55,000-share stock option grant, 25% of the underlying shares vest on April 1, 2027. The remaining shares then vest in 36 approximately equal monthly installments thereafter, creating a four-year vesting schedule tied to ongoing employment.
Are the recent Replimune (REPL) insider transactions market purchases or compensation grants?
The reported insider movements are compensation-related grants, not market trades. Both the 55,000 stock options and 36,667 RSUs were acquired at a disclosed price of $0.00 per share, reflecting awards under company equity plans rather than open-market buying or selling activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
